Therapeutic iloprost for the treatment of acute respiratory distress syndrome (ARDS) (the ThIlo trial): a prospective, randomized, multicenter phase II study

BACKGROUND: Acute respiratory distress syndrome (ARDS) is caused by rapid-onset (within hours) acute inflammatory processes in lung tissue, and it is a life-threatening condition with high mortality. The treatment of ARDS to date is focused on the prevention of further iatrogenic damage of the lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Haeberle, Helene, Prohaska, Stefanie, Martus, Peter, Straub, Andreas, Zarbock, Alexander, Marx, Gernot, Zago, Manola, Giera, Martin, Koeppen, Michael, Rosenberger, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057516/
https://www.ncbi.nlm.nih.gov/pubmed/32131881
http://dx.doi.org/10.1186/s13063-020-4163-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057516/
https://www.ncbi.nlm.nih.gov/pubmed/32131881
http://dx.doi.org/10.1186/s13063-020-4163-0

Ejemplares similares